Basel, 04 February 2025- Roche announced today that the US Food and Drug Administration has approved Susvimo ® 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision ...

Basel, 18 July 2024 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for ...

Basel, 22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...

Roche's (RHHBY) Genentech unit has received FDA approval for its eye drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema. Read more here.

Roche said that the Food and Drug Administration's decision was based on positive one-year results from the phase III of the Pagoda randomized study, which showed that Susvimo led to sustained ...

Roche's Susvimo Gets FDA Green Light for Treatment of Diabetic Retinopathy Provided by Dow Jones May 22, 2025, 4:20:00 PM. By Andrea Figueras .

Susvimo (ranibizumab injection) was approved in the U.S. in October 2021 to treat wet AMD — a disease which affects the central part of the retina called macula and causes gradual vision loss ...

On October 22, 2021 Roche announced the FDA’s approval of its ranibizumab intravitreal injection, marketed as Susvimo. Susvimo is a refillable ocular implant—requiring refills every six months ...

Basel, 22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...

Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight. PR Newswire . Wed, Apr 30, 2025, 5:31 PM 9 min read.